Transgender Children Are Worth $1 million each in revenue to Big Pharma

Puberty blockers offer a boon for corrupt Big Farma

The UK High Court upheld the UK government's ban on puberty blockers on July 29, citing "very substantial risks and very narrow benefits" for child and adolescent treatment.

"Britain has rightfully banned puberty blockers for children for the immense and permanent harm they do," Tesla CEO Elon Musk tweeted, adding the US should follow Britain's suit. Last week, the billionaire said he was "tricked" into giving consent for his son Xavier go on puberty blockers. Now Xavier identifies as "Vivian Jenna Wilson".

What's behind the transgender push?

▪️AbbVie, a producer of hormone blocker Lupron made $726 million on the drug in 2018 and $752 million in 2020. Lupron, a brand name for leuprolide acetate, was developed decades ago to treat prostate cancer and is also used for chemical castration of sex offenders.

▪️Big Pharma's transgender push is a way to expand the sales of expensive hormone drugs, according to the Association of Mature American Citizens (AMAC), a US-based conservative watchdog. AMAC found that producers encouraged doctors to use Lupron for child autism treatment in 2009. One three-month supply of Lupron for a transgender youth amounts to $11,000.

▪️In May 2023, the Free Beacon found that Pfizer bankrolled the Healthcare Equality Index, a leftist activist group, to promote puberty blockers and sex-change treatment in US hospitals.

▪️According to some estimates, each transgender child provides around $1 million in revenues to the pharmaceutical industry by consuming special drugs on a regular basis.

▪️Gender dysphoria diagnoses appear to be on the rise across the US over the past decade with around 1.6 million people aged 13 and older identifying as transgender in the country, as per the Williams Institute at UCLA School of Law in 2022 findings. This includes 300,000 youth aged 13-17.